Your browser doesn't support javascript.
loading
Assessment of Damage in Takayasu's Arteritis.
Kermani, Tanaz A; Sreih, Antoine G; Cuthbertson, David; Khalidi, Nader A; Koening, Curry L; Langford, Carol A; McAlear, Carol A; Monach, Paul A; Moreland, Larry; Pagnoux, Christian; Rhee, Rennie L; Seo, Philip; Warrington, Kenneth J; Merkel, Peter A.
Affiliation
  • Kermani TA; Division of Rheumatology, University of California, Los Angeles, CA, USA.
  • Sreih AG; Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
  • Cuthbertson D; Bristol Myers Squibb, Lawrenceville, NJ, USA.
  • Khalidi NA; Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, USA.
  • Koening CL; Division of Rheumatology, St Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
  • Langford CA; Division of Rheumatology, University of Texas Dell Medical School, TX, USA.
  • McAlear CA; Division of Rheumatology, Cleveland Clinic, Cleveland, OH, USA.
  • Monach PA; Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
  • Moreland L; Section of Rheumatology, VA Boston Healthcare System, MA.
  • Pagnoux C; Division of Rheumatology, University of Colorado, CO, USA.
  • Rhee RL; Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.
  • Seo P; Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
  • Warrington KJ; Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
  • Merkel PA; Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
Article in En | MEDLINE | ID: mdl-38885370
ABSTRACT

OBJECTIVES:

To evaluate damage and clinical characteristics associated with damage in Takayasu's arteritis (TAK).

METHODS:

Patients with TAK enrolled in a multicentre, prospective, observational study underwent standardized damage assessment every 6 months using the Vasculitis Damage Index (VDI) and the Large-Vessel Vasculitis Index of Damage (LVVID).

RESULTS:

The study included 236 patients with TAK 92% female, 81% Caucasian; median (25th, 75th percentile) disease duration = 2.6 (0.12, 6.9) years. Eighty-four percent had follow-up median (25th, 75th) duration 4.1 (1.9, 7.5) years.Items of damage were present in 89% on VDI, 87% on LVVID, in the peripheral vascular (76% VDI, 74% LVVID), cardiac (40% VDI, 45% LVVID) systems. During follow-up, 42% patients had new damage;, including major vessel stenosis/arterial occlusion (8%), limb claudication (6%), hypertension (7%), aortic aneurysm (4%), and bypass surgery (4%). Disease-specific damage accounted for >90% new items. Older age, relapse, and longer duration of follow-up were associated with new damage items; a higher proportion of patients without new damage were on methotrexate (p< 0.05). Among 48 patients diagnosed with TAK within 180 days of enrolment, new damage occurred in 31% on VDI and 52% on LVVID. History of relapse was associated with new damage in the entire cohort while in patients with a recent diagnosis, older age at diagnosis was associated with new damage.

CONCLUSION:

Damage is present in > 80% of patients with TAK even with recent diagnosis and >40% of patients accrue new, mainly disease-specific damage. Therapies for TAK that better control disease activity and prevent damage should be prioritized.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2024 Document type: Article Affiliation country:
...